← Back to Search

Other

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Phase 3
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

This trial is testing VX-548, a new medication, to see if it can help reduce pain in patients who have had abdominoplasty surgery. VX-548 likely works by blocking pain signals in the body.

Eligible Conditions
  • Acute Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: VX-548Experimental Treatment2 Interventions
Participants will receive VX-548.
Group II: Hydrocodone bitartrate/acetaminophen (HB/APAP)Active Control2 Interventions
Participants will receive HB/APAP.
Group III: PlaceboPlacebo Group2 Interventions
Participants will receive placebos matched to VX-548 and HB/APAP.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo (matched to HB/APAP)
2021
Completed Phase 3
~2770
VX-548
2022
Completed Phase 3
~3790

Find a Location

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
257 Previous Clinical Trials
33,936 Total Patients Enrolled
8 Trials studying Acute Pain
2,858 Patients Enrolled for Acute Pain

Media Library

VX-548 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05558410 — Phase 3
Acute Pain Research Study Groups: VX-548, Hydrocodone bitartrate/acetaminophen (HB/APAP), Placebo
Acute Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05558410 — Phase 3
VX-548 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558410 — Phase 3
~353 spots leftby Dec 2025